Document is current
Any future updates will be listed below
-
Authors
Nummi, Päivi
Cajuso, Tatiana
Norri, Tuukka
Taira, Aurora
Kuisma, Heli
Välimäki, Niko
Lepistö, Anna
Renkonen-Sinisalo, Laura
Koskensalo, Selja
Seppälä, Toni T.
Ristimäki, Ari
Tahkola, Kyösti
Mattila, Anne
Böhm, Jan
Mecklin, Jukka-Pekka
Siili, Emma
Pasanen, Annukka
Heikinheimo, Oskari
Bützow, Ralf
Karhu, Auli
Burns, Kathleen H.
Palin, Kimmo
Aaltonen, Lauri A.
-
Funding
Funding for this research was provided by:
University of Helsinki
- License Information
-
More Information
Article History
Received: 20 September 2024
Accepted: 8 April 2025
First Online: 22 April 2025
Declarations
:
: The study was reviewed and approved by the Finnish National Supervisory Authority for Welfare and Health, National Institute for Health and Welfare (THL/151/5.05.00/2017, THL/723/5.05.00/2018, THL/1300/5.05.00/2019), and the Ethics Committee of the Hospital District of Helsinki and Uusimaa (Dnro 133/E8/03, 408/13/03/03/2009, HUS/2509/2016, 177/13/03/03/2016). A consent was signed with the majority of samples, however in a few cases collected before 1999 a verbal consent was derived. Signed informed consent was not required in the Finnish legislation prior to that. For the samples authorization for research use came from the National Supervisory Authority for Welfare and Health (Dnro 421/04/044/06, Dnro 8048/06.01.03.01/2014, Dnro 358/32/300/05, Dnro 1476/06.01.03.01/2012).
: Not applicable.
: T.T.S. reports consultation fees from Amgen, Tillotts Pharma and Nouscom, and is a co-owner and CEO of Healthfund Finland Ltd, and in the Clinical Advisory Board and minor stakeholder of LS Cancer Diag Ltd.
